BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

444 related articles for article (PubMed ID: 27502586)

  • 1. EFFECTS: an expanded access program of everolimus for patients with subependymal giant cell astrocytoma associated with tuberous sclerosis complex.
    Fogarasi A; De Waele L; Bartalini G; Jozwiak S; Laforgia N; Verhelst H; Petrak B; Pedespan JM; Witt O; Castellana R; Crippa S; Gislimberti G; Gyorsok Z
    BMC Neurol; 2016 Aug; 16():126. PubMed ID: 27502586
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety of Everolimus in Patients Younger than 3 Years of Age: Results from EXIST-1, a Randomized, Controlled Clinical Trial.
    Jóźwiak S; Kotulska K; Berkowitz N; Brechenmacher T; Franz DN
    J Pediatr; 2016 May; 172():151-155.e1. PubMed ID: 26858193
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Everolimus for subependymal giant cell astrocytoma: 5-year final analysis.
    Franz DN; Agricola K; Mays M; Tudor C; Care MM; Holland-Bouley K; Berkowitz N; Miao S; Peyrard S; Krueger DA
    Ann Neurol; 2015 Dec; 78(6):929-38. PubMed ID: 26381530
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial.
    Franz DN; Belousova E; Sparagana S; Bebin EM; Frost M; Kuperman R; Witt O; Kohrman MH; Flamini JR; Wu JY; Curatolo P; de Vries PJ; Whittemore VH; Thiele EA; Ford JP; Shah G; Cauwel H; Lebwohl D; Sahmoud T; Jozwiak S
    Lancet; 2013 Jan; 381(9861):125-32. PubMed ID: 23158522
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-Term Use of Everolimus in Patients with Tuberous Sclerosis Complex: Final Results from the EXIST-1 Study.
    Franz DN; Belousova E; Sparagana S; Bebin EM; Frost MD; Kuperman R; Witt O; Kohrman MH; Flamini JR; Wu JY; Curatolo P; de Vries PJ; Berkowitz N; Niolat J; Jóźwiak S
    PLoS One; 2016; 11(6):e0158476. PubMed ID: 27351628
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Everolimus for subependymal giant cell astrocytoma in patients with tuberous sclerosis complex: 2-year open-label extension of the randomised EXIST-1 study.
    Franz DN; Belousova E; Sparagana S; Bebin EM; Frost M; Kuperman R; Witt O; Kohrman MH; Flamini JR; Wu JY; Curatolo P; de Vries PJ; Berkowitz N; Anak O; Niolat J; Jozwiak S
    Lancet Oncol; 2014 Dec; 15(13):1513-1520. PubMed ID: 25456370
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Everolimus long-term safety and efficacy in subependymal giant cell astrocytoma.
    Krueger DA; Care MM; Agricola K; Tudor C; Mays M; Franz DN
    Neurology; 2013 Feb; 80(6):574-80. PubMed ID: 23325902
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of everolimus on skin lesions in patients treated for subependymal giant cell astrocytoma and renal angiomyolipoma: final 4-year results from the randomized EXIST-1 and EXIST-2 studies.
    Franz DN; Budde K; Kingswood JC; Belousova E; Sparagana S; de Vries PJ; Berkowitz N; Ridolfi A; Bissler JJ
    J Eur Acad Dermatol Venereol; 2018 Oct; 32(10):1796-1803. PubMed ID: 29569806
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Maintenance therapy with everolimus for subependymal giant cell astrocytoma in patients with tuberous sclerosis (the EMINENTS study).
    Trelinska J; Dachowska I; Baranska D; Stawiski K; Kotulska K; Fendler W; Jozwiak S; Mlynarski W
    Pediatr Blood Cancer; 2017 Jun; 64(6):. PubMed ID: 27860334
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Response to everolimus in patients with giant cell astrocytoma associated to tuberous sclerosis complex].
    Mateos-González ME; López-Laso E; Vicente-Rueda J; Camino-León R; Fernández-Ramos JA; Baena-Gómez MA; Peña-Rosa MJ
    Rev Neurol; 2014 Dec; 59(11):497-502. PubMed ID: 25418144
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of everolimus on renal angiomyolipoma in pediatric patients with tuberous sclerosis being treated for subependymal giant cell astrocytoma.
    Bissler JJ; Franz DN; Frost MD; Belousova E; Bebin EM; Sparagana S; Berkowitz N; Ridolfi A; Kingswood JC
    Pediatr Nephrol; 2018 Jan; 33(1):101-109. PubMed ID: 28993887
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness and safety of everolimus treatment in patients with tuberous sclerosis complex in real-world clinical practice.
    Cockerell I; Christensen J; Hoei-Hansen CE; Holst L; Grenaa Frederiksen M; Issa-Epe AI; Nedregaard B; Solhoff R; Heimdal K; Johannessen Landmark C; Lund C; Nærland T
    Orphanet J Rare Dis; 2023 Dec; 18(1):377. PubMed ID: 38042867
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Everolimus compliance and persistence among tuberous sclerosis complex patients with renal angiomyolipoma or subependymal giant cell astrocytoma.
    Song X; Said Q; Tran O; Krueger DA; Bissler J
    Curr Med Res Opin; 2019 Jun; 35(6):1103-1110. PubMed ID: 30550347
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rapamycin and rapalogs for tuberous sclerosis complex.
    Sasongko TH; Ismail NF; Zabidi-Hussin Z
    Cochrane Database Syst Rev; 2016 Jul; 7(7):CD011272. PubMed ID: 27409709
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis.
    Krueger DA; Care MM; Holland K; Agricola K; Tudor C; Mangeshkar P; Wilson KA; Byars A; Sahmoud T; Franz DN
    N Engl J Med; 2010 Nov; 363(19):1801-11. PubMed ID: 21047224
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of mTOR inhibitor treatment in patients with tuberous sclerosis complex under 2 years of age - a multicenter retrospective study.
    Saffari A; Brösse I; Wiemer-Kruel A; Wilken B; Kreuzaler P; Hahn A; Bernhard MK; van Tilburg CM; Hoffmann GF; Gorenflo M; Hethey S; Kaiser O; Kölker S; Wagner R; Witt O; Merkenschlager A; Möckel A; Roser T; Schlump JU; Serfling A; Spiegler J; Milde T; Ziegler A; Syrbe S
    Orphanet J Rare Dis; 2019 May; 14(1):96. PubMed ID: 31053163
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of everolimus-associated adverse events in patients with tuberous sclerosis complex: a practical guide.
    Davies M; Saxena A; Kingswood JC
    Orphanet J Rare Dis; 2017 Feb; 12(1):35. PubMed ID: 28202028
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mammalian Target of Rapamycin Inhibitor Induced Complete Remission of a Recurrent Subependymal Giant Cell Astrocytoma in a Patient Without Features of Tuberous Sclerosis Complex.
    Appalla D; Depalma A; Calderwood S
    Pediatr Blood Cancer; 2016 Jul; 63(7):1276-8. PubMed ID: 26929034
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term effect of everolimus on epilepsy and growth in children under 3 years of age treated for subependymal giant cell astrocytoma associated with tuberous sclerosis complex.
    Kotulska K; Chmielewski D; Borkowska J; Jurkiewicz E; Kuczyński D; Kmieć T; Łojszczyk B; Dunin-Wąsowicz D; Jóźwiak S
    Eur J Paediatr Neurol; 2013 Sep; 17(5):479-85. PubMed ID: 23567018
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factors affecting response to everolimus therapy for subependymal giant cell astrocytomas associated with tuberous sclerosis.
    Trelinska J; Dachowska I; Kotulska K; Baranska D; Fendler W; Jozwiak S; Mlynarski W
    Pediatr Blood Cancer; 2015 Apr; 62(4):616-21. PubMed ID: 25557360
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.